

## CLAIMS

1. Use of an osmolyte in the manufacture of a medicament for the treatment of ocular disorders.
2. The use according to claim 1, wherein the osmolyte is selected from a group consisting of betaine, raffinose, sarcosine, taurine and/or any pharmaceutically acceptable derivatives thereof.
3. The use according to claim 1, wherein the osmolyte is a combination of taurine and sarcosine.
4. The use according to claim 1, wherein the osmolyte is selected from a group consisting of taurine and/or any pharmaceutically acceptable derivatives thereof.
5. The use according to claim 1, wherein the osmolyte has a concentration of 0.01 mM to 1,000 mM.
6. The use according to claim 1, wherein the osmolyte has a concentration of 100 mM to 500 mM.
7. The use according to claim 1, wherein the osmolyte has a concentration of 200 mM and 320 mM.
8. The use according to claim 1, wherein the medicament is in a dosage form of drops, ointments, gels and/or injections.
9. The use according to claim 1, wherein the medicament is administrated for at least 24 hours to 12 months.
10. The use according to claim 1, wherein the medicament is administrated for at least 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 4 weeks, 2 months, 4 months, 6 months, 9 months or 12 months.

11. The use according to claim 1, wherein the osmolyte inhibits amyloid fibrillation and dissolves amyloid fibrils.

12. The use according to claim 1 wherein the ocular disorders are Transforming Growth Factor-Beta Induced (*TGFBI*) corneal dystrophies.

13. The use according to claim 12, wherein the *TGFBI* corneal dystrophies are Bowman's layer corneal dystrophies and stromal corneal dystrophies.

14. The use according to claim 13, wherein the Bowman's layer corneal dystrophies are Reis-Buckler corneal dystrophy (RBCD) and Thiel-Behnke corneal dystrophy (TBCD).

15. The use according to claim 13, wherein the stromal corneal dystrophies are lattice corneal dystrophies (LCD), Granular Corneal Dystrophies Type I (GCD1) and Type II (GCD2).